Publicacións nas que colabora con Francisco Javier García Seara (68)

2024

  1. Impact of initiation of SGLT2 inhibitor treatment on the development of arrhythmias in patients with implantable cardiac devices

    Revista Espanola de Cardiologia

  2. Pseudotransposition of the great leads

    PACE - Pacing and Clinical Electrophysiology, Vol. 47, Núm. 2, pp. 233-235

2023

  1. Atrial fibrillation ablation in patients with arrhythmia-induced cardiomyopathy: a prospective multicentre study

    ESC Heart Failure, Vol. 10, Núm. 5, pp. 3055-3066

  2. Circulating miR-451a Expression May Predict Recurrence in Atrial Fibrillation Patients after Catheter Pulmonary Vein Ablation

    Cells, Vol. 12, Núm. 4

  3. Clinical and cost-effectiveness results of an on-call program for pacemaker implantations

    Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 936-937

  4. Plasma miR-486-5p Expression Is Upregulated in Atrial Fibrillation Patients with Broader Low-Voltage Areas

    International Journal of Molecular Sciences, Vol. 24, Núm. 20

  5. Role of Soluble ST2 Biomarker in Predicting Recurrence of Atrial Fibrillation after Electrical Cardioversion or Pulmonary Vein Isolation

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  6. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

    European Journal of Internal Medicine, Vol. 99, pp. 45-56

  2. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry

    BMC Medicine, Vol. 20, Núm. 1

  3. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry

    Europace, Vol. 24, Núm. 5, pp. 721-728

  4. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 7

  5. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 6

  6. Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

    Scientific Reports, Vol. 12, Núm. 1

  7. The Role of Fatty Acid-Binding Protein 4 in the Characterization of Atrial Fibrillation and the Prediction of Outcomes after Catheter Ablation

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

2021

  1. Correction to: Galectin-3 and soluble RAGE as new biomarkers of post-infarction cardiac remodeling (Journal of Molecular Medicine, (2021), 99, 7, (943-953), 10.1007/s00109-021-02054-6)

    Journal of Molecular Medicine

  2. Galectin-3 and soluble RAGE as new biomarkers of post-infarction cardiac remodeling

    Journal of Molecular Medicine, Vol. 99, Núm. 7, pp. 943-953

  3. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry

    BMC Medicine, Vol. 19, Núm. 1

  4. Leadless pacemaker implantation with hybrid image mapping technique in a congenital heart disease case

    HeartRhythm Case Reports, Vol. 7, Núm. 12, pp. 797-800

  5. Long-term cardiac reverse remodeling after cardiac resynchronization therapy

    Journal of Arrhythmia, Vol. 37, Núm. 3, pp. 653-659